Masataka Igeta

Masataka Igeta

Auto-generated profile, based on publicly available information

Masataka Igeta

Department of Biostatistics, Hyogo College of Medicine, Nishinomiya, Japan

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2025 in Alimentary Pharmacology & Therapeutics
Verified
Journal Article
Open access
YTYasuhiro Takagi
Yasuhiro Takagi
TSToshiyuki Sato
Toshiyuki Sato
TNTakanori Nishiguchi
Takanori Nishiguchi
ANAkira Nogami
Akira Nogami
MIMasataka Igeta
Masataka Igeta
Shinichiro ShinzakiShinichiro Shinzaki
Shinichiro Shinzaki
Background: In randomised controlled trials, mirikizumab achieved clinical remission and improved outcomes of patients with moderate to severe ulcerative colitis (UC). However, there is currently no real‐world evidence for mirikizumab.Aim: To evaluate the real‐world effectiveness and safety of mirikizumab.Methods: In a retrospective cohort study among three facilities, we included patients with UC who first received mirikizumab between June 2023 and April 2024. The primary outcome was the change in the partial Mayo score (PMS) from week 0 to 12. Secondary outcomes included changes in serum C‐reactive protein (CRP) and leucine‐rich α2‐glycoprotein (LRG) levels from week 0 to 12; clinical remission rate (PMS < 2 with rectal bleeding subscore of 0), CRP remission rate (< 3.0 mg/L), and LRG remission rate (< 12.7 μg/mL) at week 12; and adverse events during induction therapy.Results: We included 52 patients. Median (interquartile range) PMS decreased from week 0 to 12 (5 [3–6] to 2 [0–3], p < 0.001). CRP and LRG levels also decreased (CRP: 3.8 [0.9–7.3] to 1.8 [0.5–4.0] mg/L, p = 0.015; LRG: 20.1 [16.3–23.2] to 15.9 [12.8–23.2] μg/mL, p = 0.014). Rates of clinical remission, CRP remission, and LRG remission at week 12 were 44.2%, 67.3%, and 27.3%, respectively. There were no adverse events leading to permanent discontinuation of mirikizumab or death.Conclusion: This real‐world study demonstrated the short‐term effectiveness and safety of mirikizumab in patients with UC.

25 July 2013 in Blood Pressure
Verified
Journal Article
Closed access
PDF file
HRHiromi Rakugi
Hiromi Rakugi
KKKazuomi Kario
Kazuomi Kario
KEKazuaki Enya
Kazuaki Enya
MIMasataka Igeta
Masataka Igeta
YIYoshinori Ikeda
Yoshinori Ikeda
Background. Abnormal variations in night-time hypertension such as “non-dipping” type (< 10% decrease in nocturnal systolic blood pressure [SBP] from daytime SBP) are a risk factor for cardiovascular events independent of 24-h BP. Methods. As part of a randomized, double-blind study of azilsartan (20–40 mg once daily) and candesartan (8–12 mg once daily) in Japanese patients with essential hypertension, an exploratory analysis was performed using ambulatory BP monitoring (ABPM) at baseline and Week 14. Effects of study drugs on nocturnal BP variations according to patients’ nocturnal SBP dipping status were evaluated. Results. ABPM data were available for 273 patients treated with azilsartan and 275 with candesartan. In the dipping group (≥ 10% decrease from daytime SBP), azilsartan produced a greater reduction from baseline in daytime than in night-time SBP (− 14.1 and − 10.9 mmHg, respectively), and the change in daytime SBP was significantly greater with azilsartan than with candesartan (p = 0.0077). In the non-dipping group, azilsartan produced a greater reduction from baseline in night-time than in daytime SBP (− 20.2 and − 9.9 mmHg, respectively), and reductions in both night-time SBP (p = 0.02) and daytime SBP (p = 0.0042) were significantly greater with azilsartan than with candesartan. Conclusions. Once-daily azilsartan improved non-dipping night-time SBP to a greater extent than candesartan in Japanese patients with grade I–II essential hypertension.

21 June 2021 in In Vivo
Verified
Journal Article
Open access
PDF file
KTKazuo Tarutani
Kazuo Tarutani
HTHaruyuki Takaki
Haruyuki Takaki
MIMasataka Igeta
Masataka Igeta
MFMasayuki Fujiwara
Masayuki Fujiwara
AOAyako Okamura
Ayako Okamura
KYKoichiro Yamakado
Koichiro Yamakado
Background/Aim: To develop and evaluate the accuracy of augmented reality (AR)-based patient positioning systems in radiotherapy. Materials and Methods: AR head-mounted displays (AR-HMDs), which virtually superimpose a three-dimensional (3D) image generated by the digital imaging and communications in medicine (DICOM) data, have been developed. The AR-based positioning feasibility was evaluated. Then, the setup errors of three translational axes directions and rotation angles between the AR and the conventional laser-based positioning were compared. Results: The AR-based pelvic phantom positioning was feasible. The setup errors of AR-based positioning were comparable to laser-based positioning in all translational axis directions and rotation angles. The time necessary for AR-based positioning was significantly longer than that for laser-based positioning (171.0 s vs. 47.5 s, p<0.001). Conclusion: AR-based positioning for radiotherapy was feasible, and showed comparable positioning errors to those of conventional line-based positioning; however, a markedly longer setup time was necessary.

14 May 2020 in PLOS ONE
Verified
Journal Article
Open access
PDF file
MNMasamitsu Nishi
Masamitsu Nishi
TKTakashi Kimura
Takashi Kimura
MIMasataka Igeta
Masataka Igeta
MFMitsuru Furuta
Mitsuru Furuta
KSKoichi Suenaga
Koichi Suenaga
HYHiroo Yoshikawa
Hiroo Yoshikawa
Myotonic dystrophy type 1 (DM1) is a multi-system disorder caused by CTG repeats in the myotonic dystrophy protein kinase (DMPK) gene. This leads to the sequestration of splicing factors such as muscleblind-like 1/2 (MBNL1/2) and aberrant splicing in the central nervous system. We investigated the splicing patterns of MBNL1/2 and genes controlled by MBNL2 in several regions of the brain and between the grey matter (GM) and white matter (WM) in DM1 patients using RT-PCR. Compared with amyotrophic lateral sclerosis (ALS, as disease controls), the percentage of spliced-in parameter (PSI) for most of the examined exons were significantly altered in most of the brain regions of DM1 patients, except for the cerebellum. The splicing of many genes was differently regulated between the GM and WM in both DM1 and ALS. In 7 out of the 15 examined splicing events, the level of PSI change between DM1 and ALS was significantly higher in the GM than in the WM. The differences in alternative splicing between the GM and WM may be related to the effect of DM1 on the WM of the brain.

23 October 2015 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
KKKohei Kaku
Kohei Kaku
MKMasafumi Katou
Masafumi Katou
MIMasataka Igeta
Masataka Igeta
TOTakashi Ohira
Takashi Ohira
HSHiroki Sano
Hiroki Sano

1 December 2018 in Cancer Science
Verified
Journal Article
Closed access
KKKei Kimura
Kei Kimura
TYTomoki Yamano
Tomoki Yamano
MIMasataka Igeta
Masataka Igeta
AIAyako Imada
Ayako Imada
SJSong Jihyung
Song Jihyung
NTNaohiro Tomita
Naohiro Tomita